Basic Sofosbuvir Information

• International Nonproprietary Name (INN): Sofosbuvir
• Brand Names Available in United Kingdom: Sovaldi, Epclusa
• ATC Code: J05AP08
• Forms & Dosages: 400 mg film-coated tablets
• Manufacturers in United Kingdom: Gilead Sciences
• Registration Status in United Kingdom: Approved for prescription use
• OTC / Rx Classification: Prescription-only medication

Latest Research Highlights

Recent studies underscore the promising efficacy of Sofosbuvir, particularly among populations in the UK and the broader European Union. Data gathered from research spanning from 2022 to 2025 illustrates that Sofosbuvir achieves sustained virologic response (SVR) rates exceeding 95% in treatment-naive patients with various Hepatitis C virus (HCV) genotypes, specifically genotypes 1 through 4. Notably, trials such as the REALIZE study highlight its effectiveness, especially when administered in conjunction with other antiviral agents like Velpatasvir and Daclatasvir. These combinations not only streamline the treatment duration to a mere 12 weeks but maintain high cure rates without compromising patient safety or outcomes. The National Health Service (NHS) in the UK has officially acknowledged Sofosbuvir as a vital component of hepatitis C treatment protocols. This endorsement aligns with the guidelines established by the European Medicines Agency (EMA). Moreover, safety evaluations reveal that most patients tolerate Sofosbuvir well, experiencing only mild side effects such as headaches or fatigue.

Study	SVR Rate	Population	Duration
REALIZE Trial	95%	Treatment-naive HCV	12 weeks
UK Cohort Analysis	92%	Genotype 1, 2, 3, 4	12-24 weeks

Continuous research efforts seek to improve the therapeutic landscape for hepatitis C and leverage Sofosbuvir's capabilities in diverse patient settings. This ongoing focus reflects a commitment to optimising treatment strategies that benefit individuals infected with HCV.

Composition & Brand Landscape

Sofosbuvir is widely recognised under its International Nonproprietary Name (INN) and marketed under various brand names, including Sovaldi and Epclusa, primarily by Gilead Sciences. This antiviral medication comes in the form of 400 mg film-coated tablets, typically available in bottles of 28. Although the active ingredient remains the same, formulations differ when Sofosbuvir is combined with other antivirals, such as Velpatasvir.

In the United Kingdom, Sovaldi remains the most prominent and commonly prescribed choice for patients. However, other variations such as MyHep and Hepcinat Plus can be sourced from international pharmacies or through generics. Local packaging regulations ensure that all products maintain proper safety standards and integrity.

While brand choices may impact patient decisions, NHS guidelines suggest transitioning to generics when feasible, aiming to cut down overall healthcare costs.

Brand Name	Manufacturer	Strength/Dosage
Sovaldi	Gilead Sciences	400 mg
Epclusa	Gilead Sciences	400 mg + 100 mg
MyHep	Mylan	400 mg + 100 mg
Hepcinat Plus	Natco Pharma	400 mg + 60 mg

Contraindications & Special Precautions

When it comes to Sofosbuvir, understanding contraindications and special precautions is crucial for patient safety. This medication is strictly contraindicated in individuals with a known allergy to Sofosbuvir or any of its components. Co-administration with rifampin or potent P-glycoprotein inducers is also disallowed, as such interactions can significantly lessen therapeutic effectiveness.

Important considerations include the use of Sofosbuvir by pregnant or breastfeeding individuals; it's recommended only when the benefits substantially outweigh potential risks, given the scant data available about its safety during these periods. Careful evaluation is needed for those with existing conditions like severe renal impairment or hepatic decompensation, as they may require closer monitoring and possible adjustments in treatment.

The elderly should also be approached with caution due to common comorbidities, ensuring tailored medical management. Moreover, educating patients on lifestyle modifications—such as reducing alcohol intake—can improve treatment outcomes.

Condition	Recommendation
Allergy to Sofosbuvir	Absolute contraindication
Pregnancy	Risk-benefit assessment
Severe renal impairment	Caution advised

Dosage Guidelines

The standard dosage of Sofosbuvir for Hepatitis C treatment is 400 mg taken orally once per day. This regimen is often prescribed in combination with other antiviral medications, tailored to the patient’s specific HCV genotype and previous treatment history.

For adults with genotypes 1 through 4, treatment typically lasts 12 weeks. However, those with decompensated cirrhosis or resistant HCV types may be advised to extend treatment to 24 weeks, possibly using multi-drug combinations to ensure the best chance of success.

Special population groups include paediatric patients aged 12 and older who weigh at least 35 kg; they are eligible for the standard dosing. Although elderly patients do not require specific dosage adjustments, close monitoring for potential comorbidities and side effects is critical.

Healthcare providers should guide patients about handling missed doses: A forgotten dose should be taken as soon as remembered unless it’s nearly time for the next dose. In instances of confusion, doubling up should be avoided.

Population	Dosage Recommendations
Adults	400 mg once daily
Paediatric (12+ kg)	400 mg once daily
Elderly	Monitor closely; no standard adjustment required

Interactions Overview

One of the key concerns with Sofosbuvir is its potential for significant drug interactions. Healthcare professionals must diligently assess these interactions to prevent any adverse effects and ensure optimal treatment efficacy.

A primary interaction arises when Sofosbuvir is co-administered with potent P-glycoprotein inducers like rifampin. These substances can reduce Sofosbuvir's antiviral effects, meaning that managing these combinations is crucial for effective treatment.

Patients should be informed about how certain foods and beverages may also affect Sofosbuvir's action. High-fat meals, for instance, can impact the absorption of some combination therapies that include Sofosbuvir. Furthermore, limiting alcohol intake during treatment is advisable due to the risk of exacerbating liver damage and undermining the treatment’s benefits.

Monitoring is essential for anyone taking additional medications, particularly antiepileptics or herbal supplements, which are commonly prescribed in the NHS. Any unexpected side effects or changes in drug efficacy should be reported immediately. Patients must remain proactive in communicating new treatments or over-the-counter products introduced while undergoing Sofosbuvir therapy.

The MHRA encourages the use of the Yellow Card system to report any adverse interactions experienced during treatment as part of its ongoing commitment to drug safety monitoring.

Interaction Class	Recommendation
P-glycoprotein inducers	Avoid co-administration
Alcohol	Limit or avoid during treatment

Consultation and Patient Guidance

For anyone considering or already on Sofosbuvir, it’s crucial to engage in meaningful discussions with healthcare providers. Understanding not just the medication but the implications of interactions can empower patients in their treatment plans.

Adding to these concerns are the emerging reports on the interactions with common over-the-counter medications. While Sofosbuvir can be effective in treating hepatitis C, the risk of complications from drug conflicts necessitates comprehensive discussions during consultations.

Patients should prepare for their appointments by keeping a detailed list of all medications, including dietary supplements and herbal products. It enables health professionals to tailor a safe and efficient treatment plan, minimising risks associated with unintended interactions.

Understanding the Importance of Reporting

Reporting any adverse interactions is not just a personal concern but a collective responsibility that contributes to broader drug safety measures. Sofosbuvir, like any powerful antiviral, can have complications when not appropriately monitored.

Adverse effects of drug interactions can range from mild discomfort to severe health implications. The information patients provide to healthcare systems can play a vital role in ongoing safety assessments and medication efficacy studies. Using platforms like the Yellow Card system ensures that individuals are contributing to the larger picture of drug safety.

Safe Practices During Treatment

Adopting safe practices while undergoing treatment is crucial. This involves regular follow-ups with healthcare practitioners informed about the patient's entire medication regimen. It’s also beneficial to approach treatment as a collaborative effort involving the patient, healthcare providers, and any caregivers.

Being open about lifestyle choices, such as dietary habits and alcohol consumption, aids in creating a comprehensive picture that helps ensure the success of Sofosbuvir therapy.

City Delivery Overview

City	Region	Delivery Time
London	England	5–7 days
Birmingham	England	5–7 days
Manchester	England	5–7 days
Glasgow	Scotland	5–7 days
Leeds	England	5–7 days
Newcastle	England	5–9 days
Sheffield	England	5–9 days
Cardiff	Wales	5–9 days
Belfast	Northern Ireland	5–9 days
Nottingham	England	5–9 days
Bradford	England	5–9 days
Wolverhampton	England	5–9 days
Leicester	England	5–9 days